Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 22 JULY 2013

Up To Date: Current Developments In Securities Laws - May/June 2013

Blank Rome LLP
Explore more from Blank Rome LLP

A number of discussion relating to current developments in securities law.

United StatesCorporate/Commercial Law
Yelena Barychev
Yelena Barychev
Francis Dehel
Francis Dehel
Melissa Murawsky
Melissa Murawsky
Michael Plunkett
Michael Plunkett

The following articles appear in the May/June 2013 edition of Up To Date: Current Developments in Securities Laws. Click here to view the full issue.

Practice Tips And Reminders

  • The July 1st Compliance Date for Certain of the New NASDAQ and NYSE Compensation Committee Rules is Around the Corner
  • Corporate Governance Will Play an Important Role in Swaps
  • You Can't Shoot Zombie Directors

SRO Updates

  • NYSE Proposes to Move to Only Website Disclosure of Listing Application Materials and to Otherwise Streamline its Listing Application Process

PCAOB/SEC News

  • Your Auditors Will Probe Deeper into Related Party Transactions
  • Cavete Publici Officialis

Legislative Corner

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP